Navigation Links
WuXi PharmaTech Announces Second-Quarter 2012 Results
Date:8/13/2012

SHANGHAI, Aug. 13, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2012.

Highlights

  • Net Revenues Increased 28.9% Year Over Year to $130.4 Million
  • Laboratory Services Net Revenues Grew 24.7% Year Over Year to $93.6 Million
  • China-Based Laboratory Services Net Revenues Increased 27.2% Year Over Year to $70.3 Million
  • U.S.-Based Laboratory Services Net Revenues Increased 17.7% Year Over Year to $23.3 Million
  • Manufacturing Services Net Revenues Grew 41.2% Year Over Year to $36.8 Million
  • Net Revenues from China Operations Exceeded $100 Million for the First Time on a Quarterly Basis
  • Share Repurchases Totaled $10.2 Million
  • GAAP Diluted Earnings Per ADS Grew 13.4% Year Over Year to $0.28
  • Non-GAAP Diluted Earnings Per ADS Increased 12.3% Year Over Year to $0.33
  • Company Increases Full-Year 2012 Revenue Guidance to $488-$498 Million
  • Management Comment"WuXi's strong operational performance continued in the second quarter," said Dr. Ge Li, Chairman and Chief Executive Officer. "Year-over-year revenue growth accelerated to 28.9%, driven by solid demand for our broad, integrated platform of services. This revenue growth was broad-based, with each of our businesses achieving double-digit growth. I'm especially proud that this was the first quarter in which our China-based operations generated more than $100 million in net revenues. I'm also pleased that WuXi's GAAP diluted earnings per ADS increased 13.4% year over year. With these results, we met or exceeded all of our guidance for revenues and margins for the second quart
    '/>"/>

    SOURCE WuXi PharmaTech (Cayman) Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
    2. WuXi PharmaTech Announces First-Quarter 2012 Results
    3. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
    4. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
    5. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
    6. Comprehensive Care Corporation Announces Profitable Six Month Financial Results
    7. Tactical Medical Packs Announces New Disaster Medical Packs Equipping First Responders for Mass Casualty Incidents
    8. Echo Therapeutics Announces Second Quarter 2012 Financial Results
    9. Bacterin International Announces Second Quarter and Six Months 2012 Financial Results
    10. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
    11. 3SBio Inc. Announces Changes to Its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
    (Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
    (Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
    Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
    ... (Nasdaq: THOR ), a world leader in device-based ... hearts, today announced that it will report its operating results ... 1. The company will hold a conference call ... all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30 ...
    ... 2011 At the 5 ... in Barcelona, Spain (20-22 October 2011),   Merz Pharmaceuticals ... efficacy and safety of   XEOMIN ® ... Dystonia is a particularly debilitating condition ...
    Cached Medicine Technology:Thoratec Schedules Third Quarter Conference Call, Webcast 2Merz research Shows Long-term Benefits for Patients With Dystonia 2Merz research Shows Long-term Benefits for Patients With Dystonia 3Merz research Shows Long-term Benefits for Patients With Dystonia 4
    (Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
    (Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
    (Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
    (Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
    (Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
    Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
    ... , BEDFORD, Mass., July 13 Hologic, Inc. (Hologic ... leading developer, manufacturer and supplier of premium diagnostics, medical ... healthcare needs of women, today announced plans to release ... August 3, 2009 after market close. In conjunction with ...
    ... July 13 Long term care costs in Wyoming continue ... pressure on those in or near retirement. As a leader ... suite of insurance products to help people proactively plan for ... take advantage of a new program designed to simplify the ...
    ... WALTHAM, Mass., July 13 Decision Resources, one of the ... healthcare issues, finds that the rheumatoid arthritis (RA) drug market ... in 2008 to $385 million in 2013. This growth will ... to healthcare insurance, greater patient spending power and increased use ...
    ... , , , ... July 13 CareGuide, Inc., an emerging health management company, welcomes ... as Area Vice President of Sales. Both are located in Texas ... location. , , Julie Sizemore ( ...
    ... RATON, Fla., July 13 Laura E. Skellchock, M.D. at Integrative ... collagen filler for the correction of smile lines, to treat patients ... has been an avid Artefill user the past several years due ... , , "It,s the perfect ...
    ... Calif., July 13 Sit ,n Sleep, the mattress ... millions of Southern Californians, today launched a new campaign ... right mattress and improved sleep health and well-being. Widely-known ... in town, Sit ,n Sleep,s new strategic direction ...
    Cached Medicine News:Health News:Hologic to Release Third Quarter Fiscal 2009 Operating Results on Monday, August 3, 2009 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 3Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 4Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 5Health News:China's Rheumatoid Arthritis Drug Market Will More than Double by 2013 2Health News:China's Rheumatoid Arthritis Drug Market Will More than Double by 2013 3Health News:CareGuide Adds New Management Team Members 2Health News:Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 2Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 3Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 4
    Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
    The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
    ... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
    ... Resolve Immersion Oil is a clear, ... throughout most of the UV-VIS spectrum. ... and high viscosity, is non-drying and ... of 1.5150. Resolve contains no PCBs, ...
    Medicine Products: